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We would like to thank Levi Sandri and colleagues for their com-
ments regarding our recently published article [1]. The authors
support our result that neither tumour thrombosis in a major
hepatic vein (mHVTT) nor portal vein tumour thrombosis, not
invading the main portal trunk, is a contraindication for liver
resection. In addition, they proposed further an aggressive
strategy for unresectable hepatocellular carcinoma (HCC), i.e.,
associating liver partition and portal vein ligation in a staged
hepatectomy (ALPPS) [2].
HCC with macroscopic vascular invasion is a challenging situ-
ation for surgical resection [3], and major hepatic resection is
often required [1,4,5]. Considering the progressive nature of the
disease, an urgent operation is also required. These situations
complicate the decision-making process, and many cases miss
their chance for a curative resection. Since ALPPS is reportedly
associated with a rapid hypertrophy of the remnant liver [2], this
technique may be a promising strategy for treating HCC with
macroscopic vascular invasion.
We have never attempted ALLPS in this setting. Instead, we
have proposed preoperative portal vein embolization (PVE) as a
possible strategy in cases with an insufﬁcient postoperative rem-
nant liver volume [6]. Actually, among 14 patients who under-
went a major hepatic resection for mHVTT, 4 patients (29%)
underwent preoperative PVE [1]. At present, PVE may be a stan-
dard strategy with an acceptable morbidity rate [7].
The presence of portal hypertension and impaired liver func-
tion (a 15 min indocyanine green retention rate of more than
20%) are contraindications for PVE [8]. These safety restrictions
should also be applied to ALPPS, since it is a more aggressive
strategy. As Levi Sandri et al. proposed, the Child-Pugh score
and the model for end-stage liver disease score may be useful
for making treatment-related decisions.
Data on this attractive approach are now being accumulated
through a worldwide registry system. However, the available
evidence remains insufﬁcient to support the use of ALPPS in cir-
rhotic patients with HCC [2,9]. Most of the evidence regarding
ALPPS is based on patients with colorectal liver metastases, in
whom the liver function has not been severely damaged. We
expect further reports on the role of the ALPPS procedure for
HCC patients requiring major hepatectomy.
Open access under CC BY-NC-ND license.Chronic kidney disease after liver transplantation
To the Editor:
We read with interest the report by Allen et al. in a recent issue of
the Journal of Hepatology [1]. The authors are to be congratulated
on highlighting the important problem of chronic kidney disease
severe CKD (KDIGO stages 4–5) as in most previous literature,
their study additionally describes the incidence of lesser degrees
of renal injury (KDIGO stage 3) and has the beneﬁt of an iothala-
mate-measured glomerular ﬁltration rate (GFR). They found that(CKD) in liver transplant recipients. Instead of concentrating on few patients maintained ‘normal’ renal function long-term after
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